



## **JIPO and WIN Join Forces to Promote Immunotherapy and Precision Oncology in 2022**

January 4, 2022 - The *Journal of Immunotherapy and Precision Oncology* ([jipoonline.org](http://jipoonline.org)) and **WIN Consortium** ([winconsortium.org](http://winconsortium.org)) are proud to announce a strategic partnership for 2022.

Aung Naing, MD, Editor-in-Chief of JIPO says, "We at JIPO are excited about our collaboration with WIN. Our shared vision is to advance clinical practice of immunotherapy and precision oncology that transforms patient care. JIPO is a peer-reviewed, open access journal with a fair and efficient double-blinded review process. Our mission is to disseminate accurate scientific knowledge, including both positive and negative studies, related to translational science and clinical medicine." Naing further elaborates, "Our editorial board comprises renowned physicians and physician-scientists from diverse backgrounds and from different parts of the world. Our collaboration with WIN will enable us to realize our shared vision."

Razelle Kurzrock, MD, Chief Medical Officer of WIN says, "JIPO is positioned to have a high impact on the entire field of immunotherapy and precision oncology. The Worldwide Innovative Network (WIN) for precision medicine has goals well aligned with JIPO, considering its track record, including a multinational precision medicine that was the first to include transcriptomics as well as genomics in order to successfully match cancer patients with drugs. We are proud to partner with JIPO to help bring the latest knowledge about innovative therapies to patients suffering from malignancies."

JIPO and WIN will cross-promote both organization's activities throughout the year, including the [WIN 2022 Symposium](#) in Barcelona, Spain, March 14-15, 2022. Abstracts selected for presentation at the WIN meeting will be published in JIPO as a Conference Proceeding.

JIPO Editorial Fellow, Dr. Khalid Jazieh, will be interviewing members of WIN Leadership to highlight the collaboration and upcoming activities. Drs. Razelle Kurzrock, Vladimir Lazar, and Richard L. Schilsky will be interviewed. These interviews will be published on the [JIPO YouTube](#) channel in the coming weeks.

Dr. Vladimir Lazar, Chief Scientific and Operating Officer of WIN, has been appointed to the JIPO Editorial Board to represent WIN Leadership. Dr. Lazar plans to contribute an editorial to the Journal in 2022. Dr. Kurzrock has published four articles in JIPO in 2019 and 2020 ([complete list here](#)).

### *About JIPO*

Journal of Immunotherapy and Precision Oncology (JIPO) is a peer-reviewed, open-access journal that is published quarterly by the Innovative Healthcare Institute (Cincinnati, OH, USA) ([innovativehci.com](http://innovativehci.com)). JIPO aims to publish high-quality manuscripts related to the field of immunotherapy and precision oncology. For more information, please visit [jipoonline.org](http://jipoonline.org).  
Contact: Valerie Clark, JIPO Publishing Manager: [editor@innovationsjournals.com](mailto:editor@innovationsjournals.com)

### *About WIN*

WIN Consortium is a non-profit association headquartered in France. The WIN network assembles 35 world-class academic medical centers, industries (pharmaceutical and diagnostic companies), research organizations and patient advocates spanning 19 countries and 4 continents, aligned to launch trials using its genomics and transcriptomics biomarker platform to bolster Precision Oncology across the world. WIN is the organizer of the WIN symposia in Precision Oncology.  
Contact: Vladimir Lazar, Chief Scientific and Operating Officer: [vladimir.lazar@winconsortium.org](mailto:vladimir.lazar@winconsortium.org)